Baseline histologic activity predicted colectomy risk in ulcerative colitis treated with biologics, independent of clinical or endoscopic factors.

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

Mark Genovese: Crohn’s disease is a chronic, inflammatory bowel disease associated with progressive bowel damage, disability, ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

In 2024, AbbVie reported that Skyrizi and Rinvoq accounted for about $5bn in growth, with the company highlighting how the two products have captured around 50% of the market share in IBD indications ...

Omvoh is now approved in the U.S. for two types of inflammatory bowel disease (IBD), following its October 2023 approval as a ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to ...

Lilly's Omvoh receives US FDA approval to treat Crohn's disease in adults: Indianapolis Friday, January 17, 2025, 12:00 Hrs [IST] Eli Lilly and Company announced that the US Food ...

Indianapolis-based Lilly announced Thursday that the U.S. Food and Drug Administration has approved Omvoh for the treatment ...

The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active ...

More than half (53%) of patients reached remission after one year of Omvoh treatment and 46% experienced healing of the ...